Literature DB >> 21273145

Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: case report and review of the literature.

Giancarlo Ceccarelli1, Gabriella d'Ettorre, Massimo Mancone, Marco Francone, Vincenzo Vullo.   

Abstract

Highly active antiretroviral therapy has greatly reduced AIDS-related morbidity and mortality; however, its widespread use has been associated with a marked rise in the frequency of cardiovascular diseases in patients with HIV. Moreover, HIV infection is associated with accelerated coronary atherosclerosis and vasculopathy, although the mechanisms underlying these findings have not been determined. We describe the case of a 45-year-old woman with HIV/HCV coinfection, irritable bowel syndrome, and accelerated progression of coronary atherosclerosis after execution of percutaneous coronary intervention (PCI). In this case, the rapidity of progression of atherosclerosis seems linked principally to chronic inflammation and excess immune activation that can depend by a concourse of factors (chronic C hepatitis, irritable bowel syndrome, PCI execution) not directly associated with traditional risk factors. Caregivers following HIV-infected patients should be aware of the increased risk of accelerated atherogenesis in these subjects, principally in case of presence of causes of intense immune activation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21273145     DOI: 10.1016/j.carrev.2010.11.006

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  2 in total

1.  Microbial translocation and infectious diseases: what is the link?

Authors:  Gabriella D'Ettorre; Daniel Douek; Mirko Paiardini; Giancarlo Ceccarelli; Vincenzo Vullo
Journal:  Int J Microbiol       Date:  2012-10-04

Review 2.  What happens to cardiovascular system behind the undetectable level of HIV viremia?

Authors:  Gabriella d'Ettorre; Giancarlo Ceccarelli; Paolo Pavone; Pietro Vittozzi; Gabriella De Girolamo; Ivan Schietroma; Sara Serafino; Noemi Giustini; Vincenzo Vullo
Journal:  AIDS Res Ther       Date:  2016-04-27       Impact factor: 2.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.